Survival differences seen for advanced-stage laryngeal cancer

Key points
- The larynx is a common site of head and neck cancer with more than 10,000 cases annually.
- Blake Joseph LeBlanc, M.D., of Louisiana State University Health-Shreveport (LSU Health), and co-authors examined survival rates at their institution for primary surgical treatment of advanced-stage tumor with outcomes in the National Cancer Database (NCDB).
- In an analysis of 165 patients (majority male, average age 55 years) with laryngeal cancer in the LSU Health tumor registry from 1998 to 2007, 48 (29.09 percent) had clinically early-stage (I/II) disease and 117 (70.91 percent) had advanced-stage (III/IV) disease.
- Of the 117 patients with advanced-stage disease, 64 (54.70 percent) underwent primary surgical therapy to include total laryngectomy or pharyngolaryngectomy (removal of the voice box and area at the back of the mouth and throat).
The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal of the voice box), to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.
The larynx is a common site of head and neck cancer with more than 10,000 cases annually. Over the past two decades, treatment for advanced-stage laryngeal cancer has shifted from primary surgical therapy to organ preservation treatments with chemotherapy and radiation, according to study background.
Blake Joseph LeBlanc, M.D., of Louisiana State University Health-Shreveport (LSU Health), and co-authors examined survival rates at their institution for primary surgical treatment of advanced-stage tumor with outcomes in the National Cancer Database (NCDB).
In an analysis of 165 patients (majority male, average age 55 years) with laryngeal cancer in the LSU Health tumor registry from 1998 to 2007, 48 (29.09 percent) had clinically early-stage (I/II) disease and 117 (70.91 percent) had advanced-stage (III/IV) disease.
Of the 117 patients with advanced-stage disease, 64 (54.70 percent) underwent primary surgical therapy to include total laryngectomy or pharyngolaryngectomy (removal of the voice box and area at the back of the mouth and throat). Data from the NCDB shows the national rate of laryngectomy declined from 60 percent in the 1980s to 32 percent in 2007. At LSU Health, five-year survival for stage IV was 55.54 percent compared with 31.60 percent nationally. LSU Health's overall survival at all stages rate was 59.14 percent and similar to the nationwide rate, according to the study results.
"This study shows that LSU Health treats a high percentage of patients with advanced-stage laryngeal carcinoma who have lower socioeconomic status, yet still has improved survival rates compared with the NCDB over the study time period. This contributes to a growing body of literature that suggests that initial surgical therapy for advanced-stage disease may result in increased survival compared with organ preservation," authors note.
###
JAMA Otolaryngol Head Neck Surg. Published online November 27, 2014. doi:10.1001/.jamaoto.2014.2998. Available pre-embargo to the media at http://media.jamanetwork.com.
Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Cherie-Ann O. Nathan, M.D., call Sally Croom at 318-675-8769 or email scroom@lsuhsc.edu
###
Sally Croom
scroom@lsuhsc.edu318-675-8769The JAMA Network Journals
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
GuideSurvival of Patients with Advanced Ovarian Cancer
Cisplatin-based combination chemo-therapy regimens have clearly produced higher response rates, complete remission rates, and an improvement in the median survival of patients with advanced ovarian cancer. The impact on…
27 May 2006
GuideChemotherapy for Advanced Stage Epithelial Ovarian Cancer
Systemic chemotherapy is the standard treatment for metastatic epithelial ovarian cancer. Early studies utilized single alkylating agents such as melphalan or combinations of alkylating agents and antimetabolites. After…
27 May 2006
GuideTreatment of Advanced Stage Epithelial Ovarian Cancer
A scheme for the management of patients with advanced-stage epithelial ovarian cancer is presented in Figure 118-6 . The components of this approach are discussed below. Cytoreductive Surgery in Ovarian Cancer Patients…






